Based on the abovementioned findings, it can be implied that pancreatic cancer is dominated by KRAS mutations or RAS pathway genes, but other gene mutations have also been observed that may be targeted for treatment [22]. This evidence concerns the gene KRAS and pancreatic neoplasm.